Regulatory Factor X 5 (RFX5) Peptide
RFX5
宿主: 合成
BP, WB
产品编号 ABIN8110251
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Regulatory Factor X 5 (RFX5) Peptide (ABIN8110251)
抗原
RFX5
(Regulatory Factor X 5 (RFX5))
资源
合成
应用范围
Blocking Peptide (BP), Western Blotting (WB)
-
-
原理
- RFX5 Peptide
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
This is a synthetic peptide designed for use in combination with anti-RFX5 antibody ( ARP37993_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
缓冲液
- Lyophilized powder
-
储存条件
- -20 °C
-
储存方法
- For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
-
-
- RFX5 (Regulatory Factor X 5 (RFX5))
-
背景
- RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. RFX is a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.
-
分子量
- 65kDa
-
基因ID
- 5993
-
NCBI登录号
- NP_000440
-
UniProt
- P48382
抗原
-
You are here:
